We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing C... CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Show more
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology PR Newswire SINGAPORE, Dec. 5, 2023 SINGAPORE, Dec. 5, 2023 /PRNewswire/ -- CytoMed...
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update PR Newswire SINGAPORE, Nov. 17, 2023 Conference call webcast is scheduled for November 22 at 9 a.m...
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference PR Newswire SINGAPORE, Nov. 14, 2023 SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed...
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology PR Newswire SINGAPORE, Sept. 25, 2023 SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited...
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency PR Newswire SINGAPORE, Aug. 15, 2023 The MOU signed by CytoMed and Hangzhou CNK...
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology PR Newswire SINGAPORE, Aug. 1, 2023 The Company now has exclusive rights to...
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US PR Newswire SINGAPORE, July 6, 2023 SINGAPORE, July 6, 2023...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -0.943396226415 | 2.12 | 2.25 | 2.09 | 2680 | 2.18728989 | CS |
| 4 | -0.08 | -3.66972477064 | 2.18 | 2.25 | 2 | 3961 | 2.10340002 | CS |
| 12 | -1.32 | -38.5964912281 | 3.42 | 3.5076 | 1.92 | 24821 | 2.59554262 | CS |
| 26 | -1.41 | -40.1709401709 | 3.51 | 5.5 | 1.92 | 30846 | 3.8313786 | CS |
| 52 | -1.15 | -35.3846153846 | 3.25 | 9.25 | 1.92 | 143388 | 4.87199934 | CS |
| 156 | -1.9 | -47.5 | 4 | 9.25 | 1.92 | 149021 | 4.79887282 | CS |
| 260 | -1.9 | -47.5 | 4 | 9.25 | 1.92 | 149021 | 4.79887282 | CS |
Monksdream
4 hours ago
Awl416
3 months ago
Monksdream
10 months ago
Eurotradr
10 months ago
Monksdream
10 months ago
AJ Freely
10 months ago
Monksdream
10 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
